DNA topoisomerase II as a target for cancer chemotherapy

Cancer Investigation

Volumn 20, Issue 4, 2002, Pages 570-589

  Walker, Jerrylaine V ^a   Nitiss, John L ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 BIS(3,5 DIOXOPIPERAZIN 1 YL)ETHANE; ABC TRANSPORTER; BLEOMYCIN; CAMPTOTHECIN; CELL DNA; CISPLATIN; DACTINOMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; GYRASE INHIBITOR; PROTEIN P53; RAZOXANE; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CATALYSIS; DNA METABOLISM; DNA REPAIR; DNA REPLICATION; DNA STRAND BREAKAGE; DRUG ACCUMULATION; DRUG RESEARCH; DRUG TARGETING; ENZYME MECHANISM; GENE MUTATION; HUMAN; LEUKEMIA; LEUKEMOGENESIS; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; REVIEW; SECOND CANCER;

DNA TOPOISOMERASES, TYPE II; ENZYME INHIBITORS; FORECASTING; GENE EXPRESSION; HUMANS; NEOPLASMS;

EID: 0036287867     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-120002156     Document Type: Review

References (164)

1. DNA topoisomerases
2. Investigating the biological functions of DNA topoisomerases in eukaryotic cells
3. DNA topoisomerases
4. Domain of human topoisomerases I and associated functions
5. Moving one DNA double helix through another by a type II DNA topoisomerase: The story of a simple molecular machine
6. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme
7. Clinical applications of anticancer drugs targeted to topoisomerase 11
8. Topoisomerase II and the response to antileukemic therapy
9. Secondary leukemias induced by topoisomerase-targeted drugs
10. Topoisomerase II as a target for anticancer drugs: When enzymes stop being nice
11. Clinical resistance to topoisomerase-targeted drugs
12. Disassembly of the nucleus in mitotic Extracts: Membrane vesicularization, lamin disassembly, and chromosome condensation are independent processes
13. DNA topoisomerase II is required at the time of mitosis in yeast
14. DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe
15. Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme
16. Eukaryotic DNA topoisomerase II beta
17. Topoisomerase II: A specific marker for cell proliferation
18. Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells
19. Regulation of the human topoisomerase II alpha gene promoter in confluence-arrested cells
20. Physiological regulation of eukaryotic topoisomerase II
21. DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines
22. DNA topoisomerase II beta and neural development
23. Late embryonic lethality and impaired V(D)J recombination in mice lacking DNA ligase IV
24. Amsacrine etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II
25. Stabilization of the topoisomerase II-DNA cleavage complex by antineoplastic drugs: Inhibition of enzyme-mediated DNA religation by 4′-(9-acridinylamino)methanesulfonm-anisidide
26. Effects of antineoplastic drugs on the post-strand-passage dna cleavage/religation equilibrium of topoisomerase II
27. Azatoxin is a mechanistic hybrid of the topoisomerase II-targeted anticancer drugs etoposide and ellipticine
28. Structure and mechanism of DNA topoisomerase II
29. Cloning and characterization of full-length cDNAs coding for the DNA topoisomerase II beta from Chinese hamster lung cells sensitive and resistant 9-OH-Ellipticine
30. Role of topoisomerase II beta in the resistance of 9-OH-Ellipticine-resistant Chinese hamster fibroblasts to topoisomerase II inhibitors
31. Murine transgenic cells lacking DNA topoisomerase IIβ are resistant to acridines and mitoxantrone: Analysis of cytotoxicity and cleavable complex formation
32. Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines
33. XK469, a selective topoisomerase IIbeta poison
34. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin
35. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons
36. Topoisomerase-targeting anti-tumor drugs: Mechanisms of cytotoxicity and resistance
37. Camptothecin, a specific inhibitor of type I DNA Topoisomerase. Induces DNA breakage at replication forks
38. Interaction between replication forks and topoisomerase I-DNA cleavable complexes: Studies in a cell-free SV40 DNA replication system
39. Processing of topoisomerase I cleavable complexes into DNA damage by transcription
40. Cell cycle stage dependent variations in drug-induced topoisomerase II mediated DNA cleavage and cytotoxicity
41. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells
42. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA
43. DNA strand cleavage is required for replication fork arrest by a frozen topoisomerase-quinolone-DNA ternary complex
44. An antitumor drug-induced topoisomerase cleavage complex blocks a bacteriophage T4 replication fork in vivo
45. Yeast gene for a Tyr-DNA phosphodiesterase that repairs topoisomerase I complexes
46. Differential etoposide sensitivity of cells deficient in the Ku and DNA-PKcs components of the DNA-dependent protein kinase
47. DNA strand breaks: The DNA template alterations that trigger p53-dependent DNA damage response pathways
48. The topoisomerase I poison camptothecin generates a Chk1-dependent DNA damage checkpoint signal in fission yeast
49. DNA topoisomerase II as a potential factor in drug resistance of human malignancies
50. Antitopoisomerase drug action and resistance
51. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide
52. Induction of apoptosis by deregulated expression of DNA Topoisomerase IIα
53. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIα cDNA: Selective restoration of the sensitivity to DNA religation Inhibitors
54. Topoisomerase II alpha gene expression in childhood acute lymphoblastic leukemia
55. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia
56. Amplification and deletion of topoisomerase IIalpha. Associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer
57. Chemotherapy administration: Doses, infusions and choice of schedule
58. Prolonged administration of low-daily-dose etoposide: A superior dosing schedule?
59. Extended-schedule oral etoposide in selected neoplasms and overview of administration and scheduling issues
60. Ten-day schedule oral etoposide therapy in advanced childhood malignancies
61. From amplification to function: The case of the MDR1 gene
62. Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26)
63. Amplification of specific DNA sequences correlates with multi-drug resistance in Chinese hamster cells
64. Biochemical, cellular, and pharmacological aspects of the multidrug transporter
65. Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP
66. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line
67. The product of the ABC half-transporter gene ABCG (BCRP/MXR/ABCP) is expressed in the plasma membrane
68. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma
69. The LRP gene encoding a major vault protein associated with drug resistance maps proximal to MRP on chromosome 16: Evidence that chromosome breakage plays a key role in MRP or LRP gene amplification
70. An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein
71. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin
72. Drug resistance in colon cancer
73. Drug resistance in lung cancer
74. A family of drugs transporters: The multidrug resistance-associated proteins
75. Disruption of the murine MRP (Multidrug Resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione
76. Cellular resistance to topoisomerase-targeted drugs: From drug uptake to cell death
77. Expression of topoisomerases II alpha and beta in Chinese hamster lung cells resistant to topoisomerase II inhibitors
78. Mitoxantrone resistance in HL-60 leukemia cells: Reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform
79. Cloning and characterization of the 5′-flanking region of the human topoisomerase II alpha gene
80. DNA topoisomerase II alpha gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells
81. Sp3 is a bifunctional transcription regulator with modular independent activation and repression domains
82. Sp3 and Sp4 can repress transcription by competing with Sp1 for the core cis-elements on the human ADH5/FDH minimal promoter
83. Enhanced coexpression of YB-1 and DNA topoisomerase II alpha genes in human colorectal carcinomas
84. The molecular biology of the CCAAT-binding factor NF-Y
85. Stable expression of a dominant negative mutant of CCAAT binding factor/NF-Y in mouse fibroblast cells resulting in retardation of cell growth and inhibition of transcription of various cellular genes
86. p53 regulates the minimal promoter of the human topoisomerase IIα gene
87. Inhibition of DNA topoisomerase II alpha gene expression by the p53 tumor suppressor
88. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line
89. Cytoplasmic localization of a mutant M(r) 160,000 topoisomerase II alpha is associated with the loss of putative bipartite nuclear localization signals in a drug-resistant human lung cancer cell line
90. Loss of amino acids 1490Lys-Ser-Lys1492 in the COOH-terminal region of topoisomerase IIα in human small cell lung cancer cells selected for resistance to etoposide results in an extranuclear enzyme localization
91. A truncated cytoplasmic topoisomerase IIα in a drug-resistant lung cancer cell line is encoded by a TOP2α allele with a partial deletion of exon 34
92. Yeast topoisomerase II mutants resistant to anti-topoisomerase agents: Identification and characterization of New yeast topoisomerase II mutants selected for resistance to etoposide
93. Conditional expression of wild-type topoisomerase II complements a mutant enzyme in mammalian cells
94. Adenovirus-mediated human topoisomerase IIα gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells
95. Mutations in the gyrb domain of eukaryotic topoisomerase II can lead to partially dominant resistance to etoposide and amsacrine
96. Binding of etoposide to topoisomerase II in the absence of DNA: Decreased affinity as a mechanism of drug Resistance
97. Temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: A genetic system for determining the targets of topoisomerase II inhibitors
98. Analysis of yeast DNA topoisomerase II mutants resistant to the antitumor drug amsacrine
99. Using yeast to study resistance to topoisomerase II-targeting drugs
100. Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II
101. Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II
102. Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells
103. Topoisomerase II alpha mutation in leukemic cells from a patient with lineage switch AML
104. Point mutations of the topoisomerase IIα gene in patients with small cell lung cancer treated with etoposide
105. p53 status and the efficacy of cancer therapy in vivo
106. bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair
107. Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death
108. Energy coupling in DNA gyrase and the mechanism of action of novobiocin
109. DNA gyrase: Purification and catalytic properties of a fragment of gyrase B protein
110. Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: Evidence for distinct drug interaction domains on topoisomerase ii
111. Novobiocin Inhibition of DNA Excision Repair May Occur Through Effects on Mitochondrial Structure and ATP Metabolism, Not on Repair Topoisomerases
112. Novobiocin precipitates histones at concentrations normally used to inhibit eukaryotic type II topoisomerase
113. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone
114. Merbarone inhibits the catalytic activity of human topoisomerase II alpha by blocking DNA cleavage
115. Inhibitors of DNA topoisomerase II
116. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: Mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors
117. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives
118. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp
119. The capture of a DNA double helix by an ATP-dependent protein clamp: A key step in DNA transport by type II DNA topoisomerases
120. Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II
121. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor [CRF-159: A Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines
122. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the walker A consensus ATP binding domain of the alpha isoform
123. DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in saccharomyces cerevisiae
124. A novel mechanism of cell killing by anti-topoisomerase II bisdioxopiperazines
125. Stabilization of type I topoisomerase-DNA covalent complexes by actinomycin D
126. Inhibition of eukaryotic DNA topoisomerase I and II activities by indoloquinolinedione derivatives
127. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase ii-mediated DNA cleavage
128. Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: Relationship to DNA integrity and topoisomerase II
129. Aclacinomycin A stabilizes topoisomerase I covalent complexes
130. Modulation of the in vitro cardiotoxicity of doxorubicin by flavonoids
131. Dexrazoxane (ICRF-187)
132. Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer
133. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, 1CRF-187) to four distinct steps in the topoisomerase II catalytic cycle
134. Phase II trial of merbarone in patients with malignant brain tumors
135. A phase II trial of merbarone (NSC 336628) in the treatment of recurrent epithelial ovarian carcinoma. A gynecologic oncology group study
136. A phase II trial of merbarone (NSC 336628) as salvage therapy for squamous cell carcinoma of the cervix. A gynecologic oncology group study
137. Myeloid neoplasia in children treated for solid tumours
138. Two different classes of therapy-related and de-novo acute myeloid leukemia?
139. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the copenhagen series
140. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours
141. Rearrangements of the MLL Gene in Therapy-Related Acute Myeloid Leukemia in Patients Previously Treated with Agents Targeting DNA-Topoisomerase II
142. Genes on chromosomes 49, and 19 involved in 11q23 abnormalities in acute leukemia share sequence homology and/or common motifs
143. AML-1 gene rearrangement and AML-1-ETO gene expression as molecular markers of acute myeloblastic leukemia with t(8;21)
144. ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children
145. Abnormalities in the Long arm of chromosome II 11q in patients with de novo and secondary acute myelogenous leukemias and myelodysplastic syndromes
146. Sequence analysis of the breakpoint cluster region in the ALL-1 gene involved in acute leukemia
147. Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: Correlation with scaffold attachment regions and topoisomerase II consensus binding sites
148. Molecular analysis of 13 Cases of MLL/11q23 secondary acute leukemia and identification of topoisomerase II consensus-binding sequences near the chromosomal breakpoint of a secondary leukemia with the t(4;11)
149. Chromosome band 11q23 translocation breakpoints are DNA topoisomerase II cleavage sites
150. An in vivo topoisomerase II cleavage site and a DNase I hypersensitive site colocalize near exon 9 in the MLL breakpoint cluster region
151. The (4;11)(q21;q23) chromosome translocations in acute leukemias involve the VDJ recombinase
152. Etoposide causes illegitimate V(D)J recombination in human lymphoid leukemic cells
153. Secondary leukemias induced by topoisomerase-targeted drugs
154. Sequence dependence of drosophila topoisomerase II in plasmid relaxation and DNA binding
155. In vitro evolution of preferred topoisomerase II DNA cleavage sites
156. DNA topoisomerase-mediated illegitimate recombination
157. Type II DNA topoisomerase from Saccharomyces cerevisiae is a stable dimer
158. Mutagenic activities of topoisomerase inhibitors
159. Metabolites of daidzein and genistein and their biological activities
160. Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia
161. Abasic sites stimulate double-stranded DNA cleavage meditated by to topoisomerase II. DNA lesions as endogenous topoisomerase II poisons
162. Apurinic sites are position-specific topoisomerase II poisons
163. Endogenous apurinic/apyrimidinic sites in genomic DNA of mammalian tissues
164. Specific chromosomal translocations and therapy-related leukemia induced by bimolane therapy for psoriasis